Related Experiment Videos
HRT and cardiovascular disease
1MRC Epidemiology and Medical Care Unit, Wolfson Institute of Preventive Medicine, London, UK.
Insights
Hormone replacement therapy (HRT) effects on cardiovascular disease remain uncertain. Recent studies suggest HRT neither harms nor protects against coronary heart disease, necessitating further randomized controlled trials for clarity.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Clinical Trials
Background:
- Clinical decisions regarding hormone replacement therapy (HRT) and cardiovascular disease (CVD) have evolved significantly over three decades.
- Early assumptions of HRT increasing thromboembolic conditions were challenged by studies in the 1980s suggesting cardioprotective effects.
- Recent findings, including the Heart and Estrogen/progestin Replacement Study (HERS), indicate HRT has a neutral effect on coronary heart disease (CHD) incidence.
Purpose of the Study:
- To address the conflicting evidence and decision-making challenges surrounding long-term HRT use for cardiovascular health.
- To highlight the need for definitive data to guide clinical practice and patient choices regarding HRT.
Main Methods:
- Review of historical assumptions and findings related to HRT and cardiovascular outcomes.
- Analysis of recent study data, such as the HERS trial, on HRT's impact on CHD.
- Emphasis on the role of randomized controlled trials (RCTs) in establishing evidence-based conclusions.
Main Results:
- Historical perspectives show a shift from HRT increasing to potentially decreasing CVD risk.
- The HERS trial suggests HRT does not significantly alter the incidence of coronary heart disease.
- Current evidence presents a complex and often contradictory picture of HRT's cardiovascular effects.
Conclusions:
- The fluctuating conclusions on HRT's cardiovascular effects create significant clinical uncertainty.
- Further large-scale, randomized controlled trials are essential to provide stable, reliable evidence.
- Establishing clear guidelines based on robust RCT data is crucial for informed clinical decisions on HRT.
Abstract:
Conclusions influencing clinical decisions about the effects of hormone replacement therapy (HRT) on cardiovascular disease have undergone major revisions over the last 30 years. Assumptions in the early 1970s that HRT would increase thromboembolic conditions were reversed in the 1980s, when the first formal studies seemed to indicate a cardioprotective effect. The Heart and Estrogen/progestin Replacement Study (HERS) has, however, very recently suggested that HRT does not affect the incidence of coronary heart disease (CHD) one way or the other. These roller-coaster changes of direction have made decisions by doctors and their patients about the long-term use of HRT extremely difficult and need to be replaced by the stability that only further randomised controlled trials (RCTs) can now provide.